Home » Bayer Drug Succeeds in Phase III PAH Trial
Bayer Drug Succeeds in Phase III PAH Trial
Bayer reported positive data from an ongoing Phase III Patent-1 study evaluating the oral guanylate cyclase (sGC) stimulator riociguat (BAY 63-2521) as a treatment for pulmonary arterial hypertension (PAH) in treatment-naïve patients and those who have previously received an endothelin receptor antagonist or prostanoid therapy.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct